Fred Hutchinson

The National Comprehensive Cancer Network published the latest in its series of guidelines intended to inform patients and their caregivers about adverse events associated with cancer therapies.

The NIH recently announced the launch of a collaborative effort to test vaccine candidates for COVID-19 in the United States.

In this installment of In Practice, Ryan D. Cassaday, MD, explains how to negotiate the delicate balancing act required when discussing alternatives to chimeric antigen receptor T-cell therapy with patients and referring colleagues.

An FDA advisory committee today voted unanimously to recommend approval of belantamab mafodotin for patients with relapsed or refractory multiple myeloma, concluding the clinical benefits outweigh potential risks that include keratopathy.

Three organizations awarded grants totaling $6.75 million to fund research into blood cancers.

The NIH awarded a $13.65 million grant to researchers at University of California, Los Angeles, to develop chimeric antigen receptor T-cell therapies for the treatment of HIV.

Black patients with cancer have been significantly underrepresented in pharmaceutical company-sponsored clinical trials, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.

A 14% readmission rate after receipt of axicabtagene ciloleucel supports policies that require monitoring by a caregiver after discharge, according to results of a single-center study presented during the ASCO20 Virtual Scientific Program.

Patients with cancer who either had Medicaid or no health insurance derived smaller benefits from experimental therapies than standard therapies in clinical trials, according to results of a meta-analysis published in JAMA Network Open.

Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.